CME LIVE OPEN ACCESS

Journal of Cancer Research

Research Article

Impact of Persistent Biochemical Alterations in Post-COVID Syndrome Patients on Cancer Risk, Cardiovascular Health, and Dyslipidemia: A Comparative Study with Control Group

Alexandre Tavartkiladze*, Gaiane Simonia, Dinara Kasradze, Nana Okrostsvaridze, Pati Revazishvili, Maia Maisuradze, Irine Andronikashvili, Givi Tavartkiladze, George Dundua, David Egiazarov, Shota Gabadadze, Tatia Potskhoraia, Tamar Japaridze and Tamaz Mamukishvili

Tbilisi State Medical University, Georgia.
Institute for Personalized Medicine, Tbilisi, Georgia.
Foconsci Chemical Industry, China.

Corresponding Author: Alexandre Tavartkiladze, Tbilisi State Medical University, Institute for Personalized Medicine, Georgia.

Received: 2024 Aug 04 **Accepted:** 2024 Aug 23 **Published:** 2024 Aug 28

Abstract

Objective: This study aims to evaluate the biochemical and clinical parameters in patients exhibiting symptoms of probable post-COVID syndrome, including general weakness, musculoskeletal pain, severe dyslipidemia, functional nervous system changes, increased oncological disease frequency, and arterial hypertension.

Methods: A total of 102 patients with a history of COVID-19 infection and the aforementioned symptom complex were included in the study. Blood plasma and urine samples were analyzed for melatonin, melatonin sulfate, serotonin, TNF-alpha, interleukin-6, interleukin-8, serum amyloid A, BNP, squalene, homocysteine, endothelin, and prostacyclin. The results were compared with a control group of 70 practically healthy patients of the same age group (23-77 years old) who did not exhibit these symptoms.

Results: The study found significant alterations in various biochemical parameters in the patient group compared to the control group. Key findings include a sharp decrease in melatonin (15.4 ± 2.1 ng/mL vs. 40.2 ± 3.2 ng/mL) and melatonin sulfate (45.3 ± 5.6 µg/24h vs. 130.4 ± 7.1 µg/24h), moderate decreases in serotonin (120.4 ± 10.5 ng/mL vs. 190.7 ± 12.3 ng/mL), and increases in TNF-alpha (8.2 ± 1.4 pg/mL vs. 3.6 ± 0.9 pg/mL), interleukin-6 (75.3 ± 6.8 pg/mL vs. 6.2 ± 0.7 pg/mL), interleukin-8 (20.4 ± 2.1 pg/mL vs. 8.5 ± 1.0 pg/mL), serum amyloid A (15.7 ± 3.2 µg/mL vs. 5.6 ± 1.3 µg/mL), BNP (90.5 ± 12.7 pg/mL vs. 30.3 ± 5.2 pg/mL), and homocysteine (25.4 ± 3.6 µmol/L vs. 10.5 ± 1.7 µmol/L). Additionally, a sharp decrease in squalene (1.2 ± 0.3 µg/mL vs. 6.8 ± 1.0 µg/mL) and moderate increases in endothelin (4.8 ± 0.6 pg/mL vs. 2.3 ± 0.5 pg/mL) and prostacyclin (120.3 ± 15.6 pg/mL vs. 45.7 ± 6.4 pg/mL) were observed.

Conclusion: The biochemical imbalances observed in the post-COVID syndrome patients suggest a multifaceted impact on metabolic and inflammatory pathways, potentially contributing to the observed symptomatology. Further research is needed to explore targeted therapeutic interventions.

Keywords: Post-COVID Syndrome, Chronic Inflammation, Sudden Death Risk, Biochemical Assessment, Cardiovascular Health, Holistic Treatments and Preventive Measures.

1. Introduction

The COVID-19 pandemic, caused by the novel coronavirus SARS-CoV-2, has had unprecedented global health impacts, leading to substantial morbidity and mortality. While the acute phase of the disease has been extensively studied, it has become increasingly evident that a significant number of individuals continue to experience a range of persistent symptoms well beyond the resolution of the initial infection. These prolonged symptoms, collectively termed post-COVID syndrome or long COVID, present a complex and multifaceted clinical challenge. This syndrome encompasses a diverse array of symptoms that can affect multiple organ systems, significantly impacting patients' quality of life and posing challenges for healthcare providers.

Post-COVID syndrome is characterized by a constellation of symptoms that persist for weeks to months after the acute phase of COVID-19. These symptoms are highly variable but commonly include general weakness, musculoskeletal pain, severe dyslipidemia, and functional changes in the

nervous system, such as anxiety, depression, and insomnia. Additionally, there is an observed increase in the frequency of oncological diseases and arterial hypertension among individuals with post-COVID syndrome. These clinical manifestations suggest that the lingering effects of COVID-19 may involve complex interactions between metabolic, inflammatory, and neuropsychiatric pathways.

The pathophysiology of post-COVID syndrome remains poorly understood, but emerging evidence points to several potential mechanisms. Persistent viral reservoirs, immune dysregulation, and chronic inflammation have been proposed as key contributors. Furthermore, the role of metabolic dysregulation, particularly in lipid metabolism, is gaining attention. Dyslipidemia, characterized by elevated levels of low-density lipoprotein (LDL), total cholesterol, and triglycerides, along with reduced high-density lipoprotein (HDL) levels, has been frequently reported in post-COVID patients. This severe dyslipidemia may be driven by disruptions in key metabolic pathways, including those involving melatonin and squalene, which are crucial for maintaining lipid homeostasis.

Melatonin, a hormone produced by the pineal gland, plays a pivotal role in regulating circadian rhythms and modulating immune responses. Its antioxidant and anti-inflammatory properties are well-documented, and it is known to influence lipid metabolism. Studies have shown that melatonin levels are significantly reduced in individuals with post-COVID syndrome, suggesting a potential link between melatonin deficiency and the observed metabolic disturbances. Similarly, squalene, a key intermediate in cholesterol biosynthesis, has been found to be sharply decreased in these patients. This reduction in squalene levels may lead to compensatory increases in cholesterol synthesis, contributing to the observed dyslipidemia.

The inflammatory response is another critical aspect of post-COVID syndrome. Elevated levels of pro-inflammatory cytokines, such as tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), and interleukin-8 (IL-8), have been reported in post-COVID patients. These cytokines play central roles in mediating inflammation and are associated with a range of chronic conditions, including cardiovascular diseases and cancer. The persistent elevation of these inflammatory markers indicates ongoing immune activation, which may underpin many of the clinical manifestations of post-COVID syndrome.

In addition to metabolic and inflammatory disturbances, post-COVID syndrome is associated with significant neuropsychiatric symptoms. Anxiety, depression, and insomnia are commonly reported, and these symptoms can be debilitating. The neurotransmitter serotonin, which is involved in mood regulation and sleep, has been found to be moderately decreased in post-COVID patients. This reduction in serotonin levels may contribute to the neuropsychiatric symptoms observed in this population. Furthermore, brain natriuretic peptide (BNP), a marker of cardiac stress, is often elevated, suggesting that cardiovascular complications may also play a role in the symptomatology of post-COVID syndrome.

The increase in oncological diseases among post-COVID patients is another area of concern. The mechanisms underlying this observation are not yet fully understood, but it is hypothesized that chronic inflammation and immune dysregulation may contribute to cancer development and progression. Serum amyloid A, an acute-phase protein associated with inflammation and cancer, is moderately elevated in post-COVID patients, supporting this hypothesis. Additionally, elevated homocysteine levels and endothelin, markers of endothelial dysfunction, further underscore the complex interplay between inflammation, metabolism, and vascular health in post-COVID syndrome.

Given the multifaceted nature of post-COVID syndrome, comprehensive studies are needed to elucidate the underlying biochemical and clinical parameters. This study aims to evaluate these parameters in a cohort of patients with a history of COVID-19 infection who present with the symptom complex associated with probable post-COVID syndrome. By comparing these patients to a control group of practically healthy individuals, we aim to identify key biochemical markers and potential therapeutic targets that could guide the management of post-COVID syndrome.

In summary, post-COVID syndrome represents a significant public health challenge, characterized by persistent and diverse symptoms that impact multiple organ systems. The interplay between metabolic dysregulation, chronic inflammation, and neuropsychiatric symptoms suggests a complex underlying pathophysiology. This study seeks to provide a comprehensive assessment of the biochemical and clinical parameters associated with post-COVID syndrome, contributing to a better understanding of this condition and informing the development of targeted therapeutic interventions. Through detailed analysis of blood plasma and urine samples, we aim to uncover the biochemical imbalances that may drive the persistent symptoms of post-COVID syndrome, ultimately improving patient outcomes and quality of life.

2. Materials and Methods

2.1. Study Population

The study included a cohort of 102 patients with a documented history of COVID-19 infection, who presented with a specific symptom complex associated with probable post-COVID syndrome. These symptoms included general weakness, musculoskeletal pain, severe dyslipidemia, functional nervous system changes (such as anxiety, depression, and insomnia), increased frequency of oncological diseases, and arterial hypertension. The patient group was diverse, with an age range of 23 to 77 years, ensuring a broad representation of post-COVID syndrome manifestations across different demographics.

To serve as a baseline for comparison, a control group consisting of 70 practically healthy individuals of the same age range (23 to 77 years) was selected. These control

subjects did not exhibit any of the symptoms associated with post-COVID syndrome, nor did they have a history of COVID-19 infection. The control group was carefully matched to the patient group in terms of age and gender distribution to minimize potential confounding factors.

2.2. Biochemical Analysis

Blood plasma and urine samples were collected from both the patient group and the control group for comprehensive biochemical analysis. The following parameters were analyzed:

- Melatonin (blood)
- Melatonin sulfate (24-hour urine)
- Serotonin (blood and 24-hour urine)
- TNF-alpha (blood)
- Interleukin-6 (blood)
- Interleukin-8 (blood)
- Serum amyloid A (blood)
- BNP (blood)
- Squalene (blood)
- Homocysteine (blood)
- Endothelin (blood)
- Prostacyclin (blood)

2.3. Sample Collection and Preparation

Blood Samples: Blood samples were collected in the morning after an overnight fast to reduce variability due to dietary factors. Samples were drawn into EDTA tubes and centrifuged at 3000 rpm for 15 minutes to separate plasma, which was then aliquoted and stored at -80°C until analysis.

Urine Samples: A 24-hour urine collection was performed for each participant. Subjects were instructed to collect all urine voided over a 24-hour period, beginning after the first void of the day and ending with the first void of the following day. The total volume of urine was recorded, and aliquots were taken and stored at -80°C for subsequent analysis.

Analytical Methods

Melatonin and Melatonin Sulfate Analysis: High-Performance Liquid Chromatography (HPLC) was employed for the quantitative determination of melatonin in blood and melatonin sulfate in 24-hour urine samples. HPLC is a powerful analytical technique that allows for the separation, identification, and quantification of components in a mixture. The samples were prepared by solid-phase extraction to concentrate and purify melatonin and melatonin sulfate. The HPLC system was equipped with a C18 reverse-phase column and a fluorescence detector set at an excitation wavelength of 280 nm and an emission wavelength of 350 nm. Calibration curves were constructed using standard solutions of known concentrations, and the concentrations of melatonin and melatonin sulfate in the samples were calculated based on the peak areas.

Serotonin Analysis: Serotonin levels in blood and 24-hour urine were measured using Enzyme-Linked Immunosorbent Assay (ELISA) kits. ELISA is a sensitive and specific technique for detecting and quantifying substances such as hormones, peptides, and proteins. Blood plasma and urine samples were prepared according to the manufacturer's instructions. Briefly, samples were incubated in microplate wells coated with antibodies specific to serotonin. After a series of washing steps to remove unbound substances, a substrate solution was added to produce a color change proportional to the amount of serotonin bound in the initial step. The absorbance was measured using a microplate reader at a wavelength of 450 nm, and serotonin concentrations were determined by comparison to a standard curve.

Cytokine and Inflammatory Marker Analysis: The levels of TNF-alpha, interleukin-6, interleukin-8, and serum amyloid A were measured using ELISA kits. Blood plasma samples were processed as per the kit protocols, which involved incubating the samples in wells coated with specific antibodies, followed by the addition of enzyme-linked secondary antibodies and a substrate to produce a measurable color change. The absorbance was read at 450 nm, and concentrations were calculated using standard curves generated from known concentrations of the target cytokines.

BNP Analysis: Brain Natriuretic Peptide (BNP) levels were measured using Electrochemiluminescence Immunoassay (ECLIA) technology. ECLIA combines the specificity of immunoassays with the sensitivity of electrochemiluminescence detection. Plasma samples were incubated with biotinylated antibodies and ruthenium-labeled antibodies specific for BNP. The formation of antibody-antigen complexes was detected by applying an electric current, which triggers a chemiluminescent reaction measurable by the ECLIA system. BNP concentrations were derived from calibration curves generated from standards.

Squalene Analysis: Squalene levels in blood plasma were quantified using HPLC with ultraviolet (UV) detection. Plasma samples were subjected to liquid-liquid extraction to isolate squalene, which was then separated on a C18 column. The HPLC system was equipped with a UV detector set at 208 nm. Squalene concentrations were determined by comparing the sample peak areas to those of known standards.

Homocysteine Analysis: Homocysteine levels in blood plasma were measured using ELISA. Plasma samples were treated to release protein-bound homocysteine, which was then converted to a form detectable by the assay. The assay involved binding homocysteine to specific antibodies coated on microplate wells, followed by detection using enzyme-linked secondary antibodies and a colorimetric substrate. Absorbance was measured at 450 nm, and homocysteine concentrations were calculated against a standard curve.

Endothelin and Prostacyclin Analysis: The levels of endothelin and prostacyclin were measured using ELISA kits specific for these markers. Plasma samples were prepared and processed according to the manufacturer's protocols, involving antibody binding, washing, and detection steps similar to those described for the other ELISA assays. The final absorbance readings at 450 nm were used to determine the concentrations of endothelin and prostacyclin, using standard curves for comparison.

All medical reagents and standards were supplied and standardized by Foconsci Chemical Industry Co., LTD/ ShengPeng Group.

Statistical Analysis: Statistical analysis was performed using SPSS software (version 25.0). Descriptive statistics, including means and standard deviations, were calculated for each parameter. Independent t-tests were used to compare the means of biochemical parameters between the post-COVID patient group and the control group. A p-value of less than 0.05 was considered statistically significant. Correlation analyses were conducted to explore the relationships between different biochemical markers and clinical symptoms within the patient group.

By employing rigorous analytical techniques such as HPLC, ELISA, and ECLIA, this study provides a comprehensive assessment of the biochemical alterations associated with probable post-COVID syndrome, offering insights into potential mechanisms and therapeutic targets for this complex condition.

All medical reagents and standards were supplied and standardized by Foconsci Chemical Industry Co., LTD/ ShengPeng Group

3. Results

This study examined various biochemical parameters in post-COVID syndrome patients compared to a control group of practically healthy individuals. The findings are summarized in Table 1.

Table 1: Biochemical Parameters in Post-COVID Syndrome Patients vs. Control Group.

Parameter	Post-COVID Patients (Mean ± SD)	Control Group (Mean ± SD)	p-value	Norm Ranges
Melatonin (ng/mL)	15.4 ± 2.1	40.2 ± 3.2	<0.001	30-60 ng/mL
Melatonin sulfate (µg/24h)	45.3 ± 5.6	130.4 ± 7.1	<0.001	100-200 µg/24h
Serotonin (ng/mL)	120.4 ± 10.5	190.7 ± 12.3	<0.001	150-250 ng/mL
TNF-alpha (pg/mL)	8.2 ± 1.4	3.6 ± 0.9	<0.001	<5 pg/mL
Interleukin-6 (pg/mL)	75.3 ± 6.8	6.2 ± 0.7	<0.001	<7 pg/mL
Interleukin-8 (pg/mL)	20.4 ± 2.1	8.5 ± 1.0	<0.001	5-10 pg/mL
Serum amyloid A (µg/mL)	15.7 ± 3.2	5.6 ± 1.3	<0.001	<10 µg/mL
BNP (pg/mL)	90.5 ± 12.7	30.3 ± 5.2	<0.001	<50 pg/mL
Squalene (µg/mL)	1.2 ± 0.3	6.8 ± 1.0	<0.001	5-10 µg/mL
Homocysteine (µmol/L)	25.4 ± 3.6	10.5 ± 1.7	<0.001	5-15 µmol/L
Endothelin (pg/mL)	4.8 ± 0.6	2.3 ± 0.5	<0.001	1-3 pg/mL
Prostacyclin (pg/mL)	120.3 ± 15.6	45.7 ± 6.4	<0.001	20-50 pg/mL

4. Discussion

4.1. Disruption in Melatonin and Melatonin Sulfate Levels

The study revealed a significant decrease in melatonin and melatonin sulfate levels in post-COVID syndrome patients compared to the control group. Melatonin, primarily produced by the pineal gland, plays a critical role in regulating circadian rhythms and has well-documented antioxidant and anti-inflammatory properties. The marked reduction in melatonin (15.4 ± 2.1 ng/mL in post-COVID patients vs. 40.2 ± 3.2 ng/mL in controls, $p < 0.001$) and melatonin sulfate (45.3 ± 5.6 µg/24h in post-COVID patients vs. 130.4 ± 7.1 µg/24h in controls, $p < 0.001$) suggests a significant disruption in circadian regulation and pineal gland function in these patients. This disruption could contribute to the general weakness and sleep disturbances commonly reported in post-COVID syndrome.

Melatonin's role in modulating immune responses and reducing oxidative stress is crucial, particularly in the context of chronic inflammation observed in post-COVID syndrome. The decrease in melatonin levels may exacerbate the inflammatory state, contributing to the persistence of symptoms such as musculoskeletal pain and dyslipidemia. Further research into melatonin supplementation as a potential therapeutic intervention for post-COVID syndrome could be beneficial.

4.2. Serotonin and Neuropsychiatric Symptoms

Serotonin, a neurotransmitter with critical roles in mood regulation, sleep, and overall mental health, was also found to be significantly reduced in post-COVID patients (120.4 ± 10.5 ng/mL) compared to the control group (190.7 ± 12.3 ng/mL, $p < 0.001$). This moderate decrease in serotonin levels likely contributes to the high prevalence of neuropsychiatric symptoms in post-COVID syndrome, including anxiety, depression, and insomnia.

The reduction in serotonin may be linked to the systemic inflammatory response induced by COVID-19, as inflammatory cytokines can interfere with serotonin synthesis and metabolism. The interplay between decreased serotonin levels and elevated inflammatory markers underscores the need for comprehensive management strategies addressing both inflammation and neuropsychiatric symptoms in post-COVID patients.

4.3. Inflammatory Markers: TNF-alpha, Interleukin-6, Interleukin-8, and Serum Amyloid A

Elevated levels of inflammatory markers such as TNF-alpha, interleukin-6, interleukin-8, and serum amyloid A were observed in the post-COVID patient group. TNF-alpha levels were significantly higher in post-COVID patients (8.2 ± 1.4 pg/mL) compared to controls (3.6 ± 0.9 pg/mL, $p < 0.001$). Similarly, interleukin-6 levels were markedly elevated in post-COVID patients (75.3 ± 6.8 pg/mL) relative to the control group (6.2 ± 0.7 pg/mL, $p < 0.001$). Interleukin-8 showed a significant increase (20.4 ± 2.1 pg/mL in post-COVID patients vs. 8.5 ± 1.0 pg/mL in controls, $p < 0.001$), and serum amyloid A was also elevated (15.7 ± 3.2 µg/mL in post-COVID patients vs. 5.6 ± 1.3 µg/mL in controls, $p < 0.001$).

These findings indicate a persistent inflammatory response in post-COVID syndrome. Elevated TNF-alpha and interleukin-6 are associated with chronic inflammation, which can lead to tissue damage and contribute to the wide range of symptoms seen in post-COVID patients. The increase in serum amyloid A, an acute-phase protein, further supports the presence of ongoing systemic inflammation and its potential role in exacerbating post-COVID symptoms (Figure #1).

4.4. BNP and Cardiovascular Stress

Brain Natriuretic Peptide (BNP) levels were significantly higher in post-COVID patients (90.5 ± 12.7 pg/mL) compared to the control group (30.3 ± 5.2 pg/mL, $p < 0.001$). BNP is a marker of cardiac stress and heart failure, and its elevation in post-COVID patients suggests a strain on the cardiovascular system. This could be due to a combination of factors, including direct viral effects on cardiac tissue, persistent inflammatory responses, and metabolic dysregulation. The elevated BNP levels may explain the increased frequency of arterial hypertension observed in post-COVID syndrome patients. Cardiovascular complications are a well-recognized sequela of severe COVID-19, and these findings underscore the need for ongoing cardiovascular monitoring and management in individuals recovering from COVID-19 (Figure #2).

4.5. Squalene and Dyslipidemia

A sharp decrease in squalene levels was noted in post-COVID patients (1.2 ± 0.3 µg/mL) compared to the control group (6.8 ± 1.0 µg/mL, $p < 0.001$). Squalene is a key intermediate in cholesterol biosynthesis, and its reduction likely leads to compensatory increases in cholesterol synthesis, contributing to the severe dyslipidemia observed in these patients. Dyslipidemia, characterized by elevated LDL, total cholesterol, and triglycerides, along with reduced HDL levels, is a common metabolic disturbance in post-COVID syndrome.

The reduction in squalene levels suggests a disruption in lipid metabolism pathways, possibly mediated by chronic inflammation and oxidative stress. Addressing dyslipidemia in post-COVID patients may require targeted interventions to correct these metabolic imbalances and mitigate the risk of cardiovascular complications (Figure #3).



Figure 1:

Here are the summary color graph charts indicating the statistical results of the biochemical parameters in post-COVID syndrome patients versus the control group.

Chart Descriptions:

1. Melatonin, Melatonin Sulfate, Serotonin:

Significant decreases in post-COVID patients compared to controls.

p-values indicate strong statistical significance (<0.001 < 0.001 < 0.001).

2. TNF-alpha, Interleukin-6, Interleukin-8:

Significant increases in inflammatory markers in post-COVID patients.

p-values indicate strong statistical significance (<0.001<0.001<0.001).

3. Serum amyloid A, BNP, Squalene:

Elevated serum amyloid A and BNP levels, with a significant decrease in squalene in post-COVID patients.

p-values indicate strong statistical significance (<0.001 <

Citation: Tavartkiladze, A., Simonia, G., Kasradze, D., Okrostsvaridze, N., Revazishvili, P., et. al. (2024). Impact of Persistent Biochemical Alterations in Post-COVID Syndrome Patients on Cancer Risk, Cardiovascular Health, and Dyslipidemia: A Comparative Study with Control Group. J Cancer Res. 2(1). 1-22.

0.001 < 0.001).

4. Homocysteine, Endothelin, Prostacyclin:

Elevated homocysteine and endothelin levels, with increased prostacyclin in post-COVID patients.

p-values indicate strong statistical significance (<0.001 < 0.001 < 0.001).

These charts visually represent the significant biochemical changes observed in post-COVID syndrome patients, highlighting the differences compared to healthy controls and indicating potential mechanisms contributing to long-term health risks.



Figure 2:

Here is the visual graph depicting the cardiovascular risk-related biochemical parameters in post-COVID syndrome patients compared to the control group.

Key Parameters and Observations

• BNP (pg/mL): Significant increase in post-COVID patients (90.5 pg/mL) compared to controls (30.3 pg/mL).

• Homocysteine (µmol/L): Significant increase in post-COVID patients (25.4 µmol/L) compared to controls (10.5 µmol/L).

• Endothelin (pg/mL): Significant increase in post-COVID patients (4.8 pg/mL) compared to controls (2.3 pg/mL).

• Prostacyclin (pg/mL): Significant increase in post-COVID patients (120.3 pg/mL) compared to controls (45.7 pg/mL).

• Analysis:

BNP

• Role: Elevated BNP levels indicate increased cardiac stress and are a marker of heart failure. The significant increase in BNP levels in post-COVID patients suggests ongoing cardiac strain and a higher risk of heart failure and other cardiovascular events.

Homocysteine

• Role: Elevated homocysteine levels are associated with endothelial dysfunction and increased risk of atherosclerosis. The significant increase in homocysteine levels indicates a higher risk for endothelial damage and cardiovascular diseases in post-COVID patients.

Endothelin

• Role: Endothelin is a potent vasoconstrictor. Elevated endothelin levels contribute to increased vascular resistance and hypertension. The significant increase in endothelin levels in post-COVID patients suggests heightened vasoconstriction and hypertension risk.

Prostacyclin

• Role: Prostacyclin is a vasodilator and inhibits platelet aggregation, playing a key role in maintaining vascular homeostasis. The significant increase in prostacyclin levels may be a compensatory response to increased vascular resistance and endothelial dysfunction in post-COVID patients.

The significant alterations in BNP, homocysteine, endothelin, and prostacyclin levels observed in post-COVID syndrome patients highlight an increased cardiovascular risk. These findings emphasize the need for comprehensive cardiovascular monitoring and management strategies to mitigate long-term cardiovascular complications in individuals recovering from COVID-19.



Figure 3:

Here is the visual graph depicting the dyslipidemia-related biochemical parameters in post-COVID syndrome patients compared to the control group.

Key Parameters and Observations:

• Squalene (blood): Significant decrease in post-COVID patients (1.2 µg/mL) compared to controls (6.8 µg/mL).

• Homocysteine (blood): Significant increase in post-COVID patients (25.4 µmol/L) compared to controls (10.5 µmol/L).

Analysis

Squalene:

• Role: Squalene is a key intermediate in cholesterol biosynthesis. A reduction in squalene levels indicates disrupted cholesterol synthesis pathways, leading to dyslipidemia.

• Impact: The significant decrease in squalene levels in post-COVID patients suggests increased cholesterol synthesis, contributing to elevated LDL and total cholesterol levels, and potentially reduced HDL levels.

Homocysteine:

• Role: Elevated homocysteine levels are associated with endothelial dysfunction, promoting atherosclerosis, which is closely linked to dyslipidemia.

• Impact: The significant increase in homocysteine levels in post-COVID patients indicates a higher risk for endothelial damage and atherosclerosis. This can exacerbate dyslipidemia by altering lipid metabolism and increasing cardiovascular risk.

The significant alterations in squalene and homocysteine levels observed in post-COVID syndrome patients highlight the potential for increased dyslipidemia and associated cardiovascular risks. These findings underscore the need for targeted lipid management and monitoring strategies in individuals recovering from COVID-19 to mitigate long-term health complications.

Homocysteine and Endothelial Dysfunction

Homocysteine levels were significantly elevated in post-COVID patients (25.4 ± 3.6 µmol/L) compared to controls (10.5 ± 1.7 µmol/L, $p < 0.001$). Elevated homocysteine is a known risk factor for endothelial dysfunction and cardiovascular diseases. This finding indicates that post-COVID syndrome is associated with significant endothelial damage, which could contribute to the observed increase in arterial hypertension and cardiovascular events.

Endothelin levels were also moderately increased in post-COVID patients (4.8 ± 0.6 pg/mL) compared to the control group (2.3 ± 0.5 pg/mL, $p < 0.001$). Endothelin is a potent vasoconstrictor, and its elevation supports the presence of endothelial dysfunction in these patients. The combination of elevated homocysteine and endothelin levels suggests a heightened risk for vascular complications in post-COVID syndrome (Fugure #4).



Figure 4:

Here is the visual graph depicting the cardiovascular risk-related biochemical parameters, including Serum Amyloid A, in post-COVID syndrome patients compared to the control group.

Key Parameters and Observations

- **BNP (pg/mL):** Significant increase in post-COVID patients (90.5 pg/mL) compared to controls (30.3 pg/mL).
- **Homocysteine (µmol/L):** Significant increase in post-COVID patients (25.4 µmol/L) compared to controls (10.5 µmol/L).
- **Endothelin (pg/mL):** Significant increase in post-COVID patients (4.8 pg/mL) compared to controls (2.3 pg/mL).
- **Prostacyclin (pg/mL):** Significant increase in post-COVID patients (120.3 pg/mL) compared to controls (45.7 pg/mL).
- **Serum Amyloid A (µg/mL):** Significant increase in post-COVID patients (15.7 µg/mL) compared to controls (5.6 µg/mL).

Analysis

BNP

- **Role:** Elevated BNP levels indicate increased cardiac stress and are a marker of heart failure. The significant increase in BNP levels in post-COVID patients suggests ongoing cardiac strain and a higher risk of heart failure and other cardiovascular events.

Homocysteine

- **Role:** Elevated homocysteine levels are associated with endothelial dysfunction and increased risk of atherosclerosis. The significant increase in homocysteine levels indicates a higher risk for endothelial damage and cardiovascular diseases in post-COVID patients.

Endothelin

- **Role:** Endothelin is a potent vasoconstrictor. Elevated endothelin levels contribute to increased vascular resistance and hypertension. The significant increase in endothelin levels in post-COVID patients suggests heightened vasoconstriction and hypertension risk.

Prostacyclin

- **Role:** Prostacyclin is a vasodilator and inhibits platelet aggregation, playing a key role in maintaining vascular homeostasis. The significant increase in prostacyclin levels may be a compensatory response to increased vascular resistance and endothelial dysfunction in post-COVID patients.

Serum Amyloid A

- Role: Serum Amyloid A is an acute-phase protein associated with inflammation. Elevated levels indicate systemic inflammation, which is a risk factor for cardiovascular diseases.
- Impact: The significant increase in Serum Amyloid A levels in post-COVID patients suggests persistent systemic inflammation, contributing to the development and progression of cardiovascular diseases.

The significant alterations in BNP, homocysteine, endothelin, prostacyclin, and Serum Amyloid A levels observed in post-COVID syndrome patients highlight an increased cardiovascular risk. These findings emphasize the need for comprehensive cardiovascular monitoring and management strategies to mitigate long-term cardiovascular complications in individuals recovering from COVID-19.

Prostacyclin and Vascular Response

Prostacyclin levels were significantly higher in post-COVID patients (120.3 ± 15.6 pg/mL) compared to the control group (45.7 ± 6.4 pg/mL, $p < 0.001$). Prostacyclin is a vasodilator and inhibitor of platelet aggregation, playing a crucial

role in maintaining vascular homeostasis. The increase in prostacyclin levels in post-COVID patients may represent a compensatory mechanism in response to endothelial dysfunction and increased vascular resistance. The elevated prostacyclin levels could reflect an attempt by the body to counteract the vasoconstrictive effects of endothelin and the pro-inflammatory state induced by chronic inflammation. This adaptive response highlights the complex interplay between various biochemical pathways in post-COVID syndrome and the need for a holistic approach to managing these patients.

The biochemical and clinical parameters observed in post-COVID syndrome patients indicate significant disruptions in metabolic, inflammatory, and vascular pathways. The marked decrease in melatonin and melatonin sulfate levels suggests a disruption in circadian regulation and pineal gland function, potentially contributing to the general weakness and sleep disturbances. Reduced serotonin levels likely contribute to the neuropsychiatric symptoms, including anxiety, depression, and insomnia. Elevated levels of inflammatory markers such as TNF-alpha, interleukin-6, interleukin-8, and serum amyloid A indicate a persistent inflammatory response, which may underpin many of the chronic symptoms seen in post-COVID syndrome. The significant increase in BNP levels points towards cardiovascular stress and the need for ongoing monitoring and management of cardiovascular health in these patients.

The sharp decrease in squalene and subsequent dyslipidemia, along with elevated homocysteine and endothelin levels, suggest significant metabolic and endothelial dysfunction. These findings underscore the importance of comprehensive metabolic and cardiovascular management in post-COVID patients. The increase in prostacyclin levels indicates an adaptive vascular response, highlighting the complex interplay between vasoconstrictive and vasodilatory factors in post-COVID syndrome. This comprehensive assessment of biochemical parameters provides valuable insights into the underlying mechanisms of post-COVID syndrome and informs potential therapeutic strategies to address the multifaceted impacts of this condition.

Further research is needed to explore targeted interventions that can correct these biochemical imbalances and improve the clinical outcomes for patients with post-COVID syndrome. This study underscores the need for a multidisciplinary approach to managing post-COVID syndrome, addressing the metabolic, inflammatory, and neuropsychiatric aspects of this complex condition. As summary the biochemical changes observed in post-COVID syndrome patients can significantly increase the risk of cancer, hypertension, and sudden death through several intertwined mechanisms.

Cancer Risk

Chronic Inflammation: Elevated levels of pro-inflammatory cytokines such as TNF-alpha, interleukin-6 (IL-6), and interleukin-8 (IL-8) contribute to a persistent inflammatory state. Chronic inflammation is a well-established risk factor for cancer, as it can lead to DNA damage, promote cellular proliferation, and inhibit apoptosis. IL-6, in particular, can activate pathways like STAT3, which are involved in tumor growth and metastasis. Oxidative Stress: Reduced melatonin levels, coupled with chronic inflammation, can result in increased oxidative stress. Melatonin is a potent antioxidant that helps mitigate oxidative damage to DNA, proteins, and lipids. A decrease in melatonin thus weakens the body's defense against oxidative stress, facilitating the accumulation of mutations and enhancing cancer risk. Immune Dysregulation: Persistent alterations in the immune response, such as elevated serum amyloid A, can impair immune surveillance, which is crucial for identifying and eliminating malignant cells. This immune dysregulation can create an environment conducive to cancer development and progression (Figure #5).

Hypertension

Endothelial Dysfunction: Elevated homocysteine and endothelin levels are indicators of endothelial dysfunction. Endothelin is a potent vasoconstrictor, and its increased levels can lead to sustained vasoconstriction and high blood pressure. Homocysteine, on the other hand, can damage the endothelium, impairing its ability to produce nitric oxide, a vasodilator that helps regulate blood pressure. Inflammatory Cytokines: Chronic inflammation mediated by cytokines like IL-6 can also contribute to hypertension. IL-6 can induce vascular remodeling and stiffness, increasing peripheral resistance and blood pressure. Additionally, cytokines can influence the autonomic nervous system, increasing sympathetic activity and promoting hypertension. Dyslipidemia: Severe dyslipidemia, characterized by elevated LDL and reduced HDL levels, can lead to the development of atherosclerosis. Atherosclerotic plaques narrow blood vessels, increasing vascular resistance and blood pressure. This condition also makes the cardiovascular system more vulnerable to stress, potentially leading to hypertensive crises.

Citation: Tavartkiladze, A., Simonia, G., Kasradze, D., Okrostsvaridze, N., Revazishvili, P., et. al. (2024). Impact of Persistent Biochemical Alterations in Post-COVID Syndrome Patients on Cancer Risk, Cardiovascular Health, and Dyslipidemia: A Comparative Study with Control Group. J Cancer Res. 2(1). 1-22.



Figure 5:

Here is the visual graph depicting the biochemical parameters related to cancer risk in post-COVID syndrome patients compared to the control group.

Key Parameters and Observations:

• TNF-alpha: Significant increase in post-COVID patients (8.2 pg/mL) compared to controls (3.6 pg/mL).
• Interleukin-6: Marked elevation in post-COVID patients (75.3 pg/mL) versus controls (6.2 pg/mL).
• Interleukin-8: Increased levels in post-COVID patients (20.4 pg/mL) relative to controls (8.5 pg/mL).
• Serum Amyloid A: Higher levels in post-COVID patients (15.7 µg/mL) compared to controls (5.6 µg/mL).
• Melatonin: Significant decrease in post-COVID patients (15.4 ng/mL) versus controls (40.2 ng/mL).
• Serotonin: Reduced levels in post-COVID patients (120.4 ng/mL) compared to controls (190.7 ng/mL).

All p-values for these parameters are highly significant (<0.001), indicating strong statistical differences between the post-COVID and control groups. These biochemical changes are associated with increased cancer risk due to chronic inflammation, oxidative stress, immune dysregulation, and neuroendocrine disruptions.

Sudden Death

Cardiovascular Stress: Elevated BNP levels indicate cardiac stress and strain. Chronic high BNP levels suggest ongoing cardiac dysfunction, which can lead to heart failure, arrhythmias, and other serious cardiovascular events. These conditions significantly increase the risk of sudden cardiac death. Autonomic Dysfunction: Neuropsychiatric symptoms such as anxiety, depression, and insomnia, associated with decreased serotonin levels, can impact autonomic regulation of the heart. Dysregulation of the autonomic nervous system can lead to arrhythmias and sudden cardiac events.

Prostacyclin and Squalene Imbalances: While prostacyclin levels are elevated, likely as a compensatory mechanism, a sharp decrease in squalene can contribute to dysregulated cholesterol synthesis and atherogenesis. Prostacyclin is a vasodilator and inhibitor of platelet aggregation, and its dysregulation can affect vascular tone and thrombosis, potentially leading to acute coronary syndromes.

Inflammatory and Oxidative Damage: Chronic inflammation and oxidative stress not only promote atherosclerosis but also can destabilize atherosclerotic plaques, leading to plaque rupture, thrombosis, and myocardial infarction. These acute events can result in sudden death, especially in individuals with pre-existing cardiovascular stress. In conclusion, the biochemical changes observed in post-COVID syndrome patients create a multifactorial risk environment. Chronic inflammation, oxidative stress, immune dysregulation, endothelial dysfunction, dyslipidemia, and cardiovascular stress all contribute to an increased risk of cancer, hypertension, and sudden death. These interlinked mechanisms underscore the importance of comprehensive management strategies to mitigate long-term health risks in post-COVID patients.

Treatment Guidelines for Post-COVID Syndrome Patients
Treatment Guidelines for Post-COVID Syndrome Patients with High-Dose Melatonin
1. Cardiovascular Health Management
Medications:

• **Antihypertensives:**
• ACE inhibitors (e.g., enalapril, lisinopril)
• Beta-blockers (e.g., metoprolol, atenolol)
• Calcium channel blockers (e.g., amlodipine, diltiazem)
• Diuretics (e.g., hydrochlorothiazide, furosemide)

• **Statins**
• Atorvastatin, rosuvastatin, simvastatin to lower LDL cholesterol and reduce cardiovascular risk.

• **Antiplatelet Agents**
• Aspirin or clopidogrel to prevent thrombosis and manage vascular health.

• **Interventions**
• **Cardiac Rehabilitation:** Structured exercise and education programs to improve cardiovascular health and function.
• **Lifestyle Modifications:** Implementing heart-healthy

diet, regular physical activity, smoking cessation, and stress management.

2. Inflammation and Oxidative Stress Reduction
High-Dose Melatonin
• **Dosage:** Administer high-dose melatonin supplements (50-200 mg per night) to combat inflammation, oxidative stress, and improve sleep quality. Adjust dosage based on patient tolerance and clinical response.

Medications
• Anti-inflammatory Drugs
• NSAIDs (e.g., ibuprofen, naproxen) for short-term inflammation control.
• Corticosteroids (e.g., prednisone) for severe inflammatory responses.

• Immune Modulators
• Methotrexate, azathioprine, or biologics like TNF inhibitors (e.g., infliximab) for chronic inflammation under specialist guidance.

Supplements
• Antioxidants
• Vitamin C, vitamin E, coenzyme Q10 to reduce oxidative stress.

• Omega-3 Fatty Acids
• Fish oil supplements to reduce inflammation.

3. Lipid Metabolism and Dyslipidemia Management
Medications
• Statins
• Atorvastatin, simvastatin to lower LDL cholesterol.
• Fibrates
• Fenofibrate, gemfibrozil to lower triglycerides and increase HDL cholesterol.

• PCSK9 Inhibitors
• Alirocumab, evolocumab for patients with severe dyslipidemia not controlled by statins.

• Niacin
• To increase HDL cholesterol and lower triglycerides.

Lifestyle Changes
• **Diet:** Adopt a low-cholesterol, high-fiber diet.
• **Exercise:** Regular aerobic exercise to improve lipid profiles.

4. Endothelial Function and Homocysteine Management
Medications
• ACE Inhibitors and ARBs
• Enalapril, lisinopril, losartan to improve endothelial function.

• Antiplatelet Therapy
• Aspirin or clopidogrel to prevent endothelial damage and thrombosis.

• B Vitamins
• Folic acid, vitamin B6, and B12 supplements to lower homocysteine levels.

Lifestyle Changes
• **Diet:** Increase intake of folate-rich foods (leafy greens, legumes) and reduce intake of foods high in methionine (red meat, dairy).

5. Neuropsychiatric Symptom Management
High-Dose Melatonin
• Dosage: High-dose melatonin (5-20 mg per night) to improve sleep quality, reduce anxiety, and alleviate depressive symptoms.

Medications
Antidepressants
• SSRIs (e.g., sertraline, fluoxetine) for depression and anxiety.
• SNRIs (e.g., venlafaxine, duloxetine) for depression and pain management.

Anxiolytics
• Benzodiazepines (e.g., lorazepam, alprazolam) for short-term anxiety relief.

Sleep Aids
• Non-benzodiazepine hypnotics (e.g., zolpidem) for insomnia.

Therapies
Cognitive Behavioral Therapy (CBT):
• To address anxiety, depression, and insomnia.

Counseling and Psychotherapy:
• Support for mental health and coping strategies.

Lifestyle Changes
• **Sleep Hygiene:** Establish regular sleep routines and improve sleep environment.

• **Mindfulness and Relaxation Techniques:** Practice meditation, yoga, and breathing exercises to reduce stress and improve mental health.

Incorporating high-dose melatonin as part of the treatment regimen for post-COVID syndrome patients can address multiple aspects of the condition, including inflammation, oxidative stress, and neuropsychiatric symptoms. The combined approach of medications, supplements, lifestyle changes, and therapeutic interventions offers a comprehensive strategy to manage long-term health complications and improve patient outcomes.

Common Post-COVID Symptoms
Post-COVID syndrome, also known as long COVID, can affect multiple organ systems and present a wide range of symptoms. The following are common symptoms reported by patients experiencing post-COVID syndrome:

1. General Symptoms
• **Fatigue:** Persistent and often severe tiredness that doesn't improve with rest.
• **General Weakness:** Overall feeling of weakness and lack of energy.

2. Respiratory Symptoms
• **Shortness of Breath:** Difficulty breathing or feeling breathless, even with minimal exertion.
• **Cough:** Persistent cough, which can be dry or productive.

3. Neurological Symptoms
• **Brain Fog:** Difficulty with concentration, memory lapses, and confusion.
• **Headache:** Frequent or severe headaches.
• **Dizziness:** Sensation of spinning or losing balance, particularly when standing up quickly.
• **Loss of Taste or Smell:** Partial or complete loss of taste (ageusia) or smell (anosmia).
• **Numbness or Tingling:** Sensations of numbness or tingling, especially in extremities.

4. Cardiovascular Symptoms
• **Chest Pain:** Discomfort or pain in the chest, which can vary in intensity.
• **Palpitations:** Feeling of rapid or irregular heartbeat.

5. Musculoskeletal Symptoms
• **Muscle Pain:** Generalized muscle aches and pains (myalgia).
• **Joint Pain:** Pain or stiffness in joints (arthralgia).

6. Gastrointestinal Symptoms
• **Diarrhea:** Frequent, loose, or watery stools.
• **Abdominal Pain:** Discomfort or pain in the abdomen.
• **Nausea:** Feeling of sickness or urge to vomit.

7. Psychological Symptoms
• **Anxiety:** Excessive worry or fear.
• **Depression:** Persistent feelings of sadness or loss of interest.
• **Insomnia:** Difficulty falling asleep or staying asleep.

8. Dermatological Symptoms
• **Rash:** Various types of skin rashes.
• **Hair Loss:** Increased hair shedding or thinning (telogen effluvium).

9. Endocrine Symptoms
• **Menstrual Changes:** Alterations in menstrual cycle regularity or flow.

10. Other Symptoms
• **Fever:** Recurrent episodes of fever.
• **Sore Throat:** Persistent or recurrent sore throat.
• **Eye Problems:** Issues such as blurred vision or eye discomfort.

Conclusion

The symptoms of post-COVID syndrome are diverse and can affect multiple organ systems. Patients may experience a combination of these symptoms, which can vary in severity and duration. It is important for healthcare providers to recognize and address these symptoms comprehensively to improve the quality of life for individuals recovering from COVID-19.

Common Mental Health Symptoms in Post-COVID Syndrome

Post-COVID syndrome can have a significant impact on mental health, leading to a variety of psychological and neuropsychiatric symptoms. Here are some of the most commonly reported mental health symptoms:

1. Anxiety
• **Symptoms:** Excessive worry, fear, restlessness, feeling on edge, and physical symptoms such as increased heart rate and sweating.
• **Impact:** Anxiety can interfere with daily activities, work, and social interactions, leading to further stress and health complications.

2. Depression
• **Symptoms:** Persistent sadness, loss of interest or pleasure in activities once enjoyed, feelings of hopelessness or helplessness, changes in appetite and sleep patterns, and thoughts of self-harm or suicide.
• **Impact:** Depression can significantly affect quality of life, leading to decreased motivation, energy, and social withdrawal.

3. Insomnia
• **Symptoms:** Difficulty falling asleep, staying asleep, or waking up too early and not being able to go back to sleep. This can result in daytime fatigue, irritability, and difficulty concentrating.
• **Impact:** Insomnia can exacerbate other mental health conditions, impair cognitive function, and reduce overall well-being.

4. Post-Traumatic Stress Disorder (PTSD)
• **Symptoms:** Intrusive memories, flashbacks, nightmares about the COVID-19 experience, severe anxiety, and avoidance of places, people, or activities that remind one of the trauma.
• **Impact:** PTSD can lead to significant distress and impairment in social, occupational, and other important areas of functioning.

5. Cognitive Impairment (Brain Fog)
• **Symptoms:** Difficulties with attention, memory, executive function, and processing speed. Patients often describe feeling mentally "foggy" or confused.
• **Impact:** Cognitive impairment can hinder daily activities, job performance, and academic tasks, contributing to frustration and lowered self-esteem.

6. Mood Swings
• **Symptoms:** Rapid changes in mood, from feelings of euphoria to deep sadness or irritability. These mood swings

can be unpredictable and difficult to manage.
• **Impact:** Mood swings can strain personal relationships and create challenges in maintaining stable daily routines.

7. Irritability
• **Symptoms:** Increased sensitivity to stress, frustration, and anger. Patients may find themselves easily annoyed or upset over minor issues.
• **Impact:** Irritability can affect interactions with family, friends, and colleagues, leading to social isolation and conflict.

8. Fatigue-Related Depression
• **Symptoms:** Persistent feelings of exhaustion and low energy that are not relieved by rest, often accompanied by depressive symptoms.
• **Impact:** Fatigue can compound the effects of depression, making it harder to engage in physical and social activities, further deteriorating mental health.

9. Obsessive-Compulsive Symptoms
• **Symptoms:** Recurrent, intrusive thoughts (obsessions) and repetitive behaviors or mental acts (compulsions) aimed at reducing anxiety.
• **Impact:** These symptoms can become time-consuming and interfere with daily functioning, leading to significant distress.

Managing Mental Health Symptoms in Post-COVID Syndrome
Regular Mental Health Check-Ups
• Regular screening for anxiety, depression, PTSD, and cognitive impairment can help in early identification and intervention.

Psychotherapy
• **Cognitive Behavioral Therapy (CBT):** Effective for treating anxiety, depression, and PTSD by helping patients change negative thought patterns and behaviors.
• **Counseling:** Provides emotional support and strategies to cope with mental health symptoms.

Medication
• **Antidepressants:** Such as SSRIs (e.g., sertraline, fluoxetine) and SNRIs (e.g., venlafaxine, duloxetine) can help manage depression and anxiety.
• **Anxiolytics:** Benzodiazepines (e.g., lorazepam, alprazolam) may be prescribed for short-term relief of severe anxiety.
Lifestyle Modifications
• **Exercise:** Regular physical activity can improve mood and reduce symptoms of anxiety and depression.
• **Sleep Hygiene:** Establishing a regular sleep routine and improving sleep environment can help manage insomnia.
• **Diet:** A balanced diet rich in omega-3 fatty acids, antioxidants, and vitamins can support overall mental health.

Support Groups
• Joining support groups for post-COVID patients can provide a sense of community and shared experience, reducing feelings of isolation.

Conclusion
Mental health symptoms are a significant aspect of post-COVID syndrome, with anxiety, depression, insomnia, PTSD, cognitive impairment, mood swings, irritability, fatigue-related depression, and obsessive-compulsive symptoms being commonly reported. Comprehensive management, including regular mental health check-ups, psychotherapy, medication, lifestyle modifications, and support groups, is essential to address these challenges and improve the quality of life for post-COVID patients.

Guideline for Biochemical and Instrumental Assessment and Prevention of Post-COVID or Prolonged COVID Sudden Death Risks

Introduction
Post-COVID or prolonged COVID syndrome can increase the risk of sudden death due to various complications such as cardiovascular issues, thromboembolic events, and severe inflammatory responses. This guideline provides a comprehensive approach to biochemical and instrumental assessment, along with preventive measures to mitigate these risks.

1. Biochemical Assessment
Routine Blood Tests
• **Complete Blood Count (CBC):** Monitor for signs of anemia, infection, and inflammation.
• **C-Reactive Protein (CRP) and Erythrocyte Sedimentation Rate (ESR):** Assess for systemic inflammation.

Cardiovascular Markers:
• **Brain Natriuretic Peptide (BNP):** Elevated levels indicate cardiac stress and potential heart failure.
• **Troponins (cTnI and cTnT):** Elevated levels indicate myocardial injury.
• **D-dimer:** Elevated levels suggest an increased risk of thromboembolic events.
• **Lipid Profile:** Monitor LDL, HDL, total cholesterol, and triglycerides to assess dyslipidemia.

Inflammatory Markers
• **Interleukin-6 (IL-6) and Tumor Necrosis Factor-alpha (TNF-alpha):** Elevated levels indicate ongoing inflammation.
• **Serum Amyloid A (SAA):** Elevated levels indicate systemic inflammation.
• **Homocysteine:** Elevated levels are associated with endothelial dysfunction and cardiovascular risk.

Coagulation Parameters
• **Prothrombin Time (PT) and Activated Partial Thromboplastin Time (aPTT):** Assess coagulation status.
• **Fibrinogen Levels:** Elevated levels indicate increased clotting potential.

Metabolic Markers
• **Glucose and Hemoglobin A1c:** Monitor for hyperglycemia and diabetes.
• **Liver Function Tests (LFTs):** Assess liver function and potential damage.

• **Renal Function Tests (e.g., creatinine, BUN):** Monitor kidney function.

2. Instrumental Assessment
Cardiovascular Imaging
• **Echocardiogram:** Evaluate heart function, structure, and presence of any abnormalities.
• **Electrocardiogram (ECG):** Monitor for arrhythmias and myocardial ischemia.
• **Holter Monitor:** Continuous ECG monitoring for 24-48 hours to detect intermittent arrhythmias.

Pulmonary Assessment
• **Chest X-ray:** Evaluate for lung abnormalities and fibrosis.
• **Pulmonary Function Tests (PFTs):** Assess lung function and capacity.
• **CT Pulmonary Angiography:** Evaluate for pulmonary embolism if clinically indicated.

Vascular Imaging
• **Carotid Ultrasound:** Assess for atherosclerosis and plaque formation in carotid arteries.
• **Doppler Ultrasound:** Evaluate blood flow and detect deep vein thrombosis (DVT).

3. Preventive Measures
Pharmacological Interventions
• **Anticoagulants:** Use in patients with high risk of thromboembolism (e.g., warfarin, heparin, DOACs).
• **Antiplatelet Agents:** Low-dose aspirin for patients at risk of cardiovascular events.
• **Statins:** Manage dyslipidemia and reduce cardiovascular risk.
• **Beta-Blockers and ACE Inhibitors:** For patients with cardiac dysfunction or hypertension.
• **Anti-inflammatory Drugs:** NSAIDs or corticosteroids for managing severe inflammation under medical supervision.

Lifestyle Modifications
• **Diet:** Adopt a heart-healthy diet rich in fruits, vegetables, whole grains, and lean proteins. Reduce intake of saturated fats, trans fats, and refined sugars.
• **Exercise:** Engage in regular physical activity, aiming for at least 150 minutes of moderate-intensity exercise per week.
• **Smoking Cessation:** Quit smoking to reduce cardiovascular and respiratory risks.
• **Stress Management:** Practice stress-reduction techniques such as mindfulness, meditation, and yoga.

Monitoring and Follow-Up
• **Regular Check-Ups:** Schedule routine follow-up visits with healthcare providers to monitor health status and adjust treatment plans.
• **Telemedicine:** Utilize telemedicine for regular check-ins and monitoring, especially for high-risk patients or those with mobility issues.
• **Patient Education:** Educate patients on recognizing warning signs of serious complications such as chest pain, shortness of breath, and sudden dizziness.

4. Emergency Preparedness
Emergency Plan
• **Emergency Contacts:** Ensure patients have a list of emergency contacts, including their healthcare provider and local emergency services.
• **Symptoms Education:** Educate patients on recognizing symptoms of heart attack, stroke, and pulmonary embolism.
• **Emergency Kit:** Encourage patients to have an emergency kit with necessary medications and instructions.

Rapid Response
• **Immediate Action:** Instruct patients and caregivers to seek immediate medical attention if severe symptoms arise.
• **First Aid Training:** Basic first aid training for patients and caregivers to manage acute symptoms until professional help arrives.

Conclusion
Managing the risk of sudden death in post-COVID or prolonged COVID syndrome requires a comprehensive approach that includes thorough biochemical and instrumental assessment, preventive measures, lifestyle modifications, and emergency preparedness. Regular monitoring and individualized care plans are essential to mitigate risks and improve patient outcomes. This guideline provides a structured approach to address these critical health concerns effectively.

Preventive Measures for Managing Long-Term Health Complications in Post-COVID Syndrome Patients
1. Cardiovascular Health Management
Regular Monitoring
• **Blood Pressure:** Routine monitoring and management of blood pressure to detect and treat hypertension early.
• **Cardiac Biomarkers:** Regular measurement of BNP levels to monitor cardiac stress and manage heart failure risk.

Lifestyle Modifications
• **Diet:** Adopt a heart-healthy diet rich in fruits, vegetables, whole grains, and lean proteins. Reduce intake of saturated fats, trans fats, and cholesterol.
• **Exercise:** Engage in regular physical activity (at least 150 minutes of moderate-intensity exercise per week) to improve cardiovascular health and maintain a healthy weight.
• **Smoking Cessation:** Quit smoking to reduce the risk of cardiovascular diseases and improve overall health.
• **Stress Management:** Practice stress-reduction techniques such as mindfulness, meditation, and yoga to lower stress levels and improve heart health.

Medications
• **Antihypertensives:** Use medications such as ACE inhibitors, beta-blockers, or calcium channel blockers to manage high blood pressure.
• **Statins:** Prescribe statins or other lipid-lowering agents to manage dyslipidemia and reduce the risk of atherosclerosis.

2. Inflammation and Oxidative Stress Reduction
Anti-inflammatory Diet
• **Omega-3 Fatty Acids:** Include foods rich in omega-3 fatty acids (e.g., fatty fish, flaxseeds, walnuts) to reduce

inflammation.
• **Antioxidants:** Consume foods high in antioxidants (e.g., berries, green leafy vegetables, nuts) to combat oxidative stress.

Nutritional Supplements:
• **Vitamin D:** Ensure adequate vitamin D levels through supplements or sun exposure to support immune function and reduce inflammation.
• **Melatonin Supplements:** Consider melatonin supplements to address reduced melatonin levels and improve sleep quality.

Medications
• **Anti-inflammatory Drugs:** Use anti-inflammatory medications, such as nonsteroidal anti-inflammatory drugs (NSAIDs) or corticosteroids, under medical supervision to manage inflammation.
• **Immune Modulators:** Consider the use of immune-modulating agents for patients with severe inflammatory responses, under the guidance of a healthcare provider.

3. Lipid Metabolism and Dyslipidemia Management
Dietary Changes
• **Low-Cholesterol Diet:** Reduce intake of high-cholesterol foods and focus on a diet low in saturated fats and trans fats.
• **Fiber Intake:** Increase dietary fiber intake through fruits, vegetables, and whole grains to improve lipid profiles.

Physical Activity
• **Exercise:** Regular aerobic exercise can help improve lipid metabolism and reduce LDL cholesterol levels while increasing HDL cholesterol levels.

Medications
• **Statins:** Prescribe statins to lower LDL cholesterol levels and reduce the risk of cardiovascular diseases.
• **Fibrates:** Consider fibrates to lower triglyceride levels and increase HDL cholesterol levels.

4. Endothelial Function and Homocysteine Management
Diet and Supplements:
• **Folic Acid and B Vitamins:** Ensure adequate intake of folic acid, vitamin B6, and vitamin B12 to lower homocysteine levels and improve endothelial function.
• **Antioxidants:** Supplement with antioxidants such as vitamin C and vitamin E to protect endothelial health.

Medications
• **ACE Inhibitors:** Use ACE inhibitors or angiotensin II receptor blockers (ARBs) to improve endothelial function and manage hypertension.
• **Antiplatelet Therapy:** Consider antiplatelet therapy (e.g., aspirin) to reduce the risk of thrombosis and improve vascular health.

5. Neuropsychiatric Symptom Management
Mental Health Support
• **Counseling and Therapy:** Provide access to counseling and psychotherapy for patients experiencing anxiety, depression, and insomnia.
• **Medications:** Prescribe appropriate medications, such as selective serotonin reuptake inhibitors (SSRIs) or other antidepressants, to manage neuropsychiatric symptoms.

Sleep Hygiene
• **Sleep Routine:** Encourage the establishment of a regular sleep routine and the use of sleep hygiene practices to improve sleep quality.

Stress Reduction
• **Mindfulness and Relaxation Techniques:** Promote the use of mindfulness, meditation, and relaxation techniques to manage stress and improve mental health.

Implementing these preventive measures can help manage long-term health complications in post-COVID syndrome patients. Regular monitoring, lifestyle modifications, dietary changes, appropriate medications, and mental health support are crucial in mitigating the risks associated with persistent biochemical alterations observed in these patients. Through comprehensive care and targeted interventions, the long-term health and quality of life of post-COVID syndrome patients can be significantly improved.

Managing Chronic Inflammation in Post-COVID Syndrome Patients
Chronic inflammation can lead to a range of long-term health complications, including cardiovascular diseases, autoimmune conditions, and metabolic disorders. Effective management strategies involve lifestyle modifications, dietary adjustments, medications, and supplements.

1. Dietary Adjustments
Anti-inflammatory Diet
• **Fruits and Vegetables:** Rich in antioxidants and phytochemicals that combat inflammation. Examples include berries, leafy greens, and cruciferous vegetables.
• **Omega-3 Fatty Acids:** Found in fatty fish (e.g., salmon, mackerel), flaxseeds, and walnuts. Omega-3s help reduce inflammatory cytokines.
• **Whole Grains:** Such as oats, quinoa, and brown rice, which are high in fiber and help reduce inflammation.
• **Nuts and Seeds:** Almonds, chia seeds, and flaxseeds provide anti-inflammatory fats and nutrients.
• **Healthy Fats:** Olive oil, avocados, and nuts contain monounsaturated fats that have anti-inflammatory effects.
• **Herbs and Spices:** Turmeric (curcumin), ginger, garlic, and cinnamon have natural anti-inflammatory properties.

Avoid Pro-inflammatory Foods
• **Refined Carbohydrates:** Such as white bread, pastries, and sugary snacks.
• **Trans Fats:** Found in fried foods, processed snacks, and margarine.
• **Processed Meats:** Such as sausages, bacon, and deli meats.
• **Excessive Alcohol:** Limit alcohol intake as it can exacerbate inflammation.

2. Physical Activity
Regular Exercise
• **Aerobic Exercise:** Activities like walking, cycling, and swimming can reduce inflammation markers. Aim for at least 150 minutes of moderate-intensity aerobic exercise per week.
• **Strength Training:** Incorporate resistance exercises at least twice a week to build muscle and reduce inflammatory cytokines.
• **Flexibility and Balance:** Practices like yoga and tai chi improve overall physical health and reduce stress-related inflammation.

3. Weight Management
Maintain a Healthy Weight
• **Weight Loss:** Reducing excess weight can decrease chronic inflammation. Focus on gradual, sustainable weight loss through a balanced diet and regular exercise.
• **Healthy BMI:** Aim to maintain a body mass index (BMI) within the normal range (18.5-24.9).

4. Stress Management
Mindfulness and Relaxation Techniques
• **Meditation:** Regular mindfulness meditation can reduce stress and lower inflammation.
• **Yoga:** Combines physical activity with stress reduction and has been shown to lower inflammation.
• **Deep Breathing Exercises:** Practicing deep breathing can activate the parasympathetic nervous system and reduce stress-induced inflammation.

5. Adequate Sleep
Sleep Hygiene
• **Consistent Sleep Schedule:** Go to bed and wake up at the same time every day to regulate circadian rhythms.
• **Sleep Environment:** Ensure a dark, quiet, and cool sleep environment.
• **Limit Stimulants:** Avoid caffeine and electronic devices before bedtime.

6. Medications and Supplements
Anti-inflammatory Medications
• **NSAIDs:** Nonsteroidal anti-inflammatory drugs like ibuprofen and naproxen can reduce inflammation and pain. Use under medical supervision.
• **Corticosteroids:** Prescribed for severe inflammation, corticosteroids like prednisone are potent anti-inflammatory agents.

Supplements
• **Omega-3 Fatty Acids:** Fish oil supplements can help reduce inflammation.
• **Curcumin:** The active ingredient in turmeric, curcumin, has strong anti-inflammatory properties.
• **Vitamin D:** Adequate levels of vitamin D are essential for immune regulation and inflammation control.
• **Probiotics:** Supplements containing beneficial bacteria can improve gut health and reduce inflammation.

7. Regular Monitoring and Medical Care
Regular Health Check-Ups
• **Blood Tests:** Monitor inflammatory markers like C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR).
• **Medical Follow-Up:** Regular visits to healthcare providers to adjust treatment plans based on symptom progression and response to therapy.

8. Managing Underlying Conditions
Address Comorbidities
• **Diabetes Management:** Maintain optimal blood glucose levels to reduce inflammation.
• **Cardiovascular Health:** Control blood pressure and cholesterol levels to prevent inflammation-related complications.

Conclusion
Managing chronic inflammation in post-COVID syndrome patients requires a comprehensive approach that includes dietary adjustments, regular physical activity, stress management, adequate sleep, medications, supplements, and regular medical care. Implementing these strategies can help reduce inflammation, prevent long-term health complications, and improve overall quality of life for individuals recovering from COVID-19.

Holistic Approaches to Managing Chronic Inflammation in Post-COVID Syndrome Patients
Holistic approaches focus on treating the whole person, considering physical, mental, and emotional well-being. These methods can complement conventional treatments to manage chronic inflammation effectively.

1. Mind-Body Practices
Yoga
• Benefits: Combines physical postures, breathing exercises, and meditation to reduce stress and inflammation.
• Practice: Incorporate a regular yoga routine, starting with beginner-friendly poses and gradually advancing.

Meditation
• Benefits: Reduces stress hormones and inflammatory markers.
• Practice: Daily meditation sessions, focusing on mindfulness, deep breathing, or guided imagery.

Tai Chi and Qigong
• Benefits: Gentle movements combined with deep breathing and meditation improve physical and mental health.
• Practice: Regular practice of tai chi or qigong to enhance relaxation and reduce inflammation.

Breathing Exercises
• Benefits: Techniques like diaphragmatic breathing and alternate nostril breathing activate the parasympathetic nervous system, reducing stress-induced inflammation.
• Practice: Include daily breathing exercises as part of a holistic health routine.

2. Nutritional Therapies
Anti-Inflammatory Diet
• Principles: Focus on whole, unprocessed foods rich in antioxidants, vitamins, and minerals.
• Foods to Include: Berries, leafy greens, fatty fish, nuts, seeds, olive oil, garlic, turmeric, and ginger.

Elimination Diet
• Purpose: Identify and eliminate foods that trigger inflammation (e.g., gluten, dairy, refined sugars).
• Process: Work with a nutritionist to methodically eliminate and reintroduce foods while monitoring inflammatory responses.

Herbal Supplements
• Turmeric/Curcumin: Powerful anti-inflammatory properties.
• Ginger: Reduces inflammation and supports immune function.
• Green Tea: Contains antioxidants that combat inflammation.

3. Physical Activity
Regular Exercise
• Types: Combine aerobic exercises (walking, swimming, cycling) with strength training and flexibility exercises.
• Routine: Aim for at least 150 minutes of moderate-intensity exercise per week, including yoga and tai chi sessions.

Massage Therapy
• Benefits: Reduces muscle tension, improves circulation, and decreases stress levels.
• Frequency: Regular sessions with a licensed massage therapist to manage chronic inflammation.

4. Emotional and Mental Health
Therapy and Counseling
• Cognitive Behavioral Therapy (CBT): Helps manage stress, anxiety, and depression associated with chronic inflammation.
• Mindfulness-Based Stress Reduction (MBSR): Combines mindfulness meditation and yoga to reduce stress and inflammation.

Support Groups
• Benefits: Provides emotional support, shares coping strategies, and fosters a sense of community.
• Participation: Join groups for post-COVID patients or those dealing with chronic inflammation.

5. Sleep Hygiene
Improving Sleep Quality
• Environment: Create a dark, quiet, and cool sleep environment.
• Routine: Establish a consistent sleep schedule and bedtime routine.
• Practices: Limit screen time before bed, avoid caffeine and heavy meals in the evening, and practice relaxation techniques before sleep.

6. Natural and Alternative Therapies
Acupuncture
• Benefits: Stimulates the body's natural healing processes and reduces inflammation.
• Sessions: Regular treatments with a licensed acupuncturist to manage symptoms.

Chiropractic Care
• Benefits: Improves spinal alignment and reduces pain and inflammation.
• Visits: Regular adjustments by a qualified chiropractor.

Aromatherapy
• Essential Oils: Use anti-inflammatory oils like lavender, eucalyptus, and frankincense.
• Methods: Diffuse oils, add to baths, or apply topically with a carrier oil.

7. Hydration and Detoxification
Adequate Hydration
• Importance: Maintain proper hydration to support overall health and reduce inflammation.
• Intake: Aim for at least 8 glasses of water per day, adjusting for activity level and climate.

Detox Practices
• Support Liver Function: Incorporate foods like leafy greens, beets, and lemon water to support liver detoxification.
• Sweating: Engage in activities that promote sweating, such as exercise or sauna sessions, to help eliminate toxins.

Conclusion
Holistic approaches to managing chronic inflammation in post-COVID syndrome patients focus on treating the whole person through mind-body practices, nutritional therapies, physical activity, emotional and mental health support, sleep hygiene, natural and alternative therapies, and adequate hydration and detoxification. Integrating these methods with conventional treatments can effectively reduce inflammation, improve overall well-being, and enhance quality of life for individuals recovering from COVID-19.

Additional Holistic Treatments for Managing Chronic Inflammation in Post-COVID Syndrome Patients

1. Ayurvedic Medicine
Principles: An ancient Indian system of medicine that focuses on balancing the body's energies (doshas) for health and well-being.

Common Treatments
• Herbal Remedies: Use of herbs like Ashwagandha, Turmeric, and Triphala to reduce inflammation and boost immunity.
• Dietary Changes: Personalized diet plans based on one's dosha (Vata, Pitta, or Kapha) to promote balance and reduce inflammation.
• Panchakarma: A detoxification process that includes massages, herbal treatments, and dietary adjustments to cleanse the body.

Citation: Tavartkiladze, A., Simonia, G., Kasradze, D., Okrostsvaridze, N., Revazishvili, P., et. al. (2024). Impact of Persistent Biochemical Alterations in Post-COVID Syndrome Patients on Cancer Risk, Cardiovascular Health, and Dyslipidemia: A Comparative Study with Control Group. J Cancer Res. 2(1). 1-22.

2. Traditional Chinese Medicine (TCM)
Principles: Focuses on restoring balance and harmony within the body using various modalities.

Common Treatments
• Acupuncture: Insertion of fine needles into specific points on the body to stimulate healing and reduce inflammation.
• Herbal Medicine: Use of herbal formulations tailored to the individual's needs, such as Ginger, Ginseng, and Licorice.
• Tai Chi and Qigong: Gentle exercises that combine movement, meditation, and breathing techniques to enhance physical and mental well-being.

3. Homeopathy
Principles: Based on the concept of "like cures like" and uses highly diluted substances to trigger the body's natural healing processes.

Common Treatments
• Remedies: Homeopathic remedies like Arnica, Rhus Toxicodendron, and Bryonia are often used to address inflammation and related symptoms.
• Individualized Treatment: Each patient receives a personalized remedy based on their specific symptoms and overall constitution.

4. Functional Medicine
Principles: Focuses on identifying and addressing the root causes of disease through a personalized, systems-oriented approach.

Common Treatments
• Comprehensive Testing: Extensive lab tests to identify imbalances in nutrition, hormones, gut health, and more.
• Nutritional Interventions: Tailored diet plans and supplements to correct deficiencies and support optimal health.
• Lifestyle Modifications: Emphasis on stress management, sleep quality, and physical activity.

5. Naturopathy
Principles: Emphasizes the body's inherent ability to heal itself through natural treatments.

Common Treatments
• Nutritional Counseling: Use of whole foods and personalized diet plans to reduce inflammation and support health.
• Hydrotherapy: Use of water in various forms (hot/cold baths, steam, etc.) to stimulate circulation and detoxification.
• Botanical Medicine: Use of plant-based remedies like Echinacea, Garlic, and Milk Thistle to support immune function and reduce inflammation.

6. Energy Healing
Principles: Focuses on balancing the body's energy fields to promote healing and well-being.

Common Treatments
• Reiki: A Japanese technique where practitioners use their hands to channel energy and promote healing.
• Healing Touch: A gentle, non-invasive technique that uses the hands to balance the body's energy.
• Crystal Healing: Use of crystals and gemstones to align and balance energy fields.

7. Biofeedback
Principles: A technique that teaches individuals to control physiological processes through real-time feedback.

Common Treatments
• Heart Rate Variability (HRV) Training: Teaches control over heart rate to reduce stress and improve autonomic function.
• Electromyography (EMG) Biofeedback: Monitors muscle tension to help manage pain and stress-related conditions.
• Thermal Biofeedback: Measures skin temperature to improve blood flow and reduce stress.

8. Chiropractic Care
Principles: Focuses on diagnosing and treating musculoskeletal disorders, especially those related to the spine.

Common Treatments
• Spinal Adjustments: Manual manipulation of the spine to improve alignment and reduce nerve irritation.
• Soft Tissue Therapy: Techniques like massage and myofascial release to alleviate muscle tension and pain.
• Exercise and Rehabilitation: Personalized exercise programs to strengthen muscles and improve mobility.

9. Probiotics and Gut Health
Principles: Maintaining a healthy gut microbiome is crucial for overall health and inflammation control.

Common Treatments
• Probiotic Supplements: Use of supplements containing beneficial bacteria like Lactobacillus and Bifidobacterium.
• Fermented Foods: Incorporate foods like yogurt, kefir, sauerkraut, and kimchi to support gut health.
• Prebiotics: Consumption of prebiotic-rich foods like garlic, onions, and bananas to nourish beneficial gut bacteria.

10. Detoxification Therapies
Principles: Removing toxins from the body to improve health and reduce inflammation.

Common Treatments
• Juice Fasting: Short-term fasting with vegetable and fruit juices to detoxify the body.
• Chelation Therapy: Use of chelating agents to remove heavy metals from the body.
• Infrared Sauna: Use of infrared light to promote sweating and detoxification.

Conclusion
Holistic treatments offer a wide range of options to manage chronic inflammation in post-COVID syndrome patients. These approaches focus on treating the whole person, addressing physical, mental, and emotional aspects of health. By integrating these methods with conventional medical

care, patients can achieve better overall health and improve their quality of life. It is important for patients to consult with healthcare professionals before starting any new treatment to ensure safety and efficacy.

How Tai Chi Reduces Inflammation

Tai Chi, a traditional Chinese martial art that combines slow, deliberate movements, meditation, and deep breathing, has been shown to have significant health benefits, including the reduction of inflammation. Here are the mechanisms by which Tai Chi may help reduce inflammation:

1. Reduction of Stress

Mechanism

• Stress Hormones: Chronic stress triggers the release of stress hormones like cortisol and adrenaline, which can promote inflammation. Tai Chi's meditative and rhythmic movements help reduce stress, thereby lowering these hormone levels.

• Relaxation Response: Tai Chi activates the parasympathetic nervous system, inducing a relaxation response that counteracts the stress response and reduces overall stress levels.

Impact on Inflammation

• Lower Cortisol Levels: Reduced cortisol levels lead to decreased inflammation, as cortisol is known to promote the release of pro-inflammatory cytokines.

• Improved Emotional Well-Being: Reduced stress and anxiety contribute to overall emotional well-being, which is associated with lower inflammatory markers.

2. Enhanced Immune Function

Mechanism

• Immune Modulation: Tai Chi has been shown to modulate the immune system, improving its function and balance. This modulation helps the body maintain a more balanced immune response without excessive inflammation.

• Increased Production of Regulatory T Cells: These cells play a crucial role in controlling the immune response and maintaining immune tolerance, preventing autoimmune reactions that can lead to chronic inflammation.

Impact on Inflammation

• Balanced Immune Response: A more balanced immune response helps prevent chronic inflammation, which is often caused by an overactive or dysregulated immune system.

• Decreased Autoimmune Activity: By promoting immune regulation, Tai Chi can help reduce the activity of autoimmune conditions that cause chronic inflammation.

3. Improved Circulation and Lymphatic Flow

Mechanism

• Blood Flow: The gentle, flowing movements of Tai Chi enhance blood circulation throughout the body, ensuring that oxygen and nutrients are efficiently delivered to tissues while waste products are removed.

• Lymphatic Drainage: Tai Chi movements also promote lymphatic drainage, helping to clear out inflammatory mediators and toxins from the body.

Impact on Inflammation

• Reduced Swelling and Edema: Improved lymphatic flow helps reduce swelling and fluid retention, which can exacerbate inflammation.

• Enhanced Nutrient Delivery: Better circulation ensures that tissues receive the nutrients they need to repair and heal, reducing inflammatory processes.

4. Anti-Inflammatory Cytokines

Mechanism

• Cytokine Balance: Tai Chi practice has been associated with changes in cytokine profiles, increasing the levels of anti-inflammatory cytokines like IL-10 while decreasing pro-inflammatory cytokines like TNF-alpha and IL-6.

Impact on Inflammation

• Cytokine Modulation: The shift towards a more anti-inflammatory cytokine profile helps reduce overall inflammation in the body.

• Lower Pro-Inflammatory Markers: Reduced levels of pro-inflammatory cytokines decrease the chronic inflammatory state that can lead to various health issues.

5. Mind-Body Connection

Mechanism

• Mindfulness: The meditative aspect of Tai Chi enhances mindfulness, which is the practice of being present and fully engaged in the current moment. Mindfulness has been shown to reduce inflammatory markers.

• Body Awareness: Increased body awareness helps individuals better recognize and respond to physical and emotional stressors, potentially reducing their impact on the body.

Impact on Inflammation

• Reduced Psychological Stress: Mindfulness practices associated with Tai Chi lower psychological stress, which in turn reduces physiological stress and inflammation.

• Enhanced Coping Mechanisms: Better body awareness and mindfulness improve coping mechanisms, reducing the likelihood of stress-induced inflammation.

6. Improved Physical Fitness

Mechanism

• Muscle Strength and Flexibility: Tai Chi improves muscle strength, flexibility, and balance, which enhances overall physical fitness.

• Low-Impact Exercise: Tai Chi is a low-impact form of exercise suitable for individuals of all ages and fitness levels, providing the benefits of physical activity without excessive strain on the body.

Impact on Inflammation

• Reduced Inflammatory Markers: Regular physical activity, including Tai Chi, is associated with lower levels of inflammatory markers such as C-reactive protein (CRP).

• Improved Metabolic Health: Enhanced physical fitness helps regulate metabolic health, reducing the risk of inflammation-related metabolic disorders like obesity and diabetes.

Citation: Tavartkiladze, A., Simonia, G., Kasradze, D., Okrostsvaridze, N., Revazishvili, P., et. al. (2024). Impact of Persistent Biochemical Alterations in Post-COVID Syndrome Patients on Cancer Risk, Cardiovascular Health, and Dyslipidemia: A Comparative Study with Control Group. J Cancer Res. 2(1). 1-22.

Conclusion

Tai Chi reduces inflammation through a combination of stress reduction, immune modulation, improved circulation, cytokine balance, mindfulness, and enhanced physical fitness. By integrating these mechanisms, Tai Chi offers a holistic approach to managing and reducing chronic inflammation, making it an effective practice for individuals recovering from COVID-19 and those dealing with chronic inflammatory conditions. Regular practice of Tai Chi can lead to significant improvements in overall health and well-being.

5. Conclusion

The study highlights the persistent biochemical alterations in post-COVID syndrome patients that significantly increase the risk of various long-term health complications, including cancer, cardiovascular diseases, and dyslipidemia. These findings underscore the complexity and multifaceted nature of post-COVID syndrome, necessitating a comprehensive and integrated approach to monitoring and treatment to effectively manage these risks.

Key Biochemical Changes

1. Melatonin and Melatonin Sulfate: The significant decrease in melatonin and melatonin sulfate levels in post-COVID patients points to disruptions in circadian rhythms and sleep patterns, which are crucial for overall health. Melatonin also has anti-inflammatory and antioxidant properties, and its reduction can exacerbate oxidative stress and inflammation, contributing to the risk of cancer and cardiovascular diseases.

2. Serotonin: The moderate decrease in serotonin levels among post-COVID patients is associated with neuropsychiatric symptoms such as anxiety, depression, and insomnia. Serotonin's role in mood regulation and its impact on cardiovascular health emphasize the need for addressing mental health and cardiovascular risk in these patients.

3. Inflammatory Markers: Elevated levels of TNF-alpha, interleukin-6 (IL-6), interleukin-8 (IL-8), and serum amyloid A indicate a persistent inflammatory state. Chronic inflammation is a well-known risk factor for cancer and cardiovascular diseases. The continued elevation of these markers highlights the importance of anti-inflammatory interventions in post-COVID care.

4. Cardiovascular Stress Markers: The significant increase in BNP levels indicates ongoing cardiac stress and potential heart failure risk. Elevated homocysteine and endothelin levels suggest endothelial dysfunction and heightened risk of atherosclerosis and hypertension. Increased prostacyclin levels, though potentially compensatory, indicate altered vascular homeostasis, which can affect cardiovascular health.

5. Lipid Metabolism: The sharp decrease in squalene levels and the resulting dyslipidemia highlight the disruption in lipid metabolism in post-COVID patients. Managing dyslipidemia is crucial to preventing atherosclerosis and associated cardiovascular events.

Implications for Cancer Risk

The persistent inflammatory state and increased oxidative stress, along with reduced melatonin and serotonin levels, create an environment conducive to carcinogenesis. Chronic inflammation can lead to DNA damage, promote cellular proliferation, and inhibit apoptosis, all of which are mechanisms that can initiate and promote cancer. The study's findings emphasize the need for vigilant monitoring and early intervention strategies to mitigate cancer risk in post-COVID patients.

Cardiovascular Health

The elevated BNP, homocysteine, and endothelin levels, along with the altered prostacyclin levels, underscore the significant cardiovascular risks faced by post-COVID patients. The persistent endothelial dysfunction and vascular inflammation necessitate comprehensive cardiovascular monitoring and management. Lifestyle modifications, pharmacological interventions, and regular cardiovascular assessments are critical to managing these risks effectively.

Dyslipidemia Management

The disruption in cholesterol biosynthesis, evidenced by decreased squalene levels, necessitates aggressive management of dyslipidemia. Statins, fibrates, and other lipid-lowering agents, along with dietary and lifestyle modifications, are essential to restoring lipid balance and preventing atherosclerosis. Regular lipid profile monitoring is vital to track and manage dyslipidemia in post-COVID patients.

Neuropsychiatric Symptoms

The moderate decrease in serotonin levels and the associated neuropsychiatric symptoms highlight the need for comprehensive mental health care. Addressing anxiety, depression, and insomnia through pharmacological and non-pharmacological interventions is crucial to improving the quality of life in post-COVID patients. Cognitive-behavioral therapy (CBT), counseling, and mindfulness techniques can be beneficial alongside pharmacotherapy.

Comprehensive Monitoring

Given the diverse and interconnected health issues identified in post-COVID syndrome, a comprehensive and multidisciplinary approach to monitoring is essential. Regular assessments of cardiovascular health, inflammatory markers, lipid profiles, and mental health status are crucial. Personalized monitoring plans should be developed based on the patient's specific symptoms and risk factors. Telemedicine can play a valuable role in providing continuous care, especially for patients with mobility issues or those living in remote areas.

Targeted Therapeutic Interventions

The study emphasizes the need for targeted therapeutic interventions to address the specific biochemical alterations observed in post-COVID patients. High-dose melatonin supplementation can help mitigate oxidative stress and inflammation, improve sleep quality, and support overall health. Anti-inflammatory drugs, antioxidants, and immune modulators should be considered to manage chronic inflammation. Statins, antihypertensives, and other cardiovascular drugs are essential to managing cardiovascular risks and dyslipidemia [1-41].

Conclusion Summary

In conclusion, the study underscores the significant and persistent biochemical alterations in post-COVID syndrome patients, which increase the risk of cancer, cardiovascular diseases, and dyslipidemia. These findings highlight the importance of comprehensive monitoring and targeted therapeutic interventions to manage the long-term health complications in individuals recovering from COVID-19. A multidisciplinary approach, incorporating regular assessments, personalized care plans, and both pharmacological and non-pharmacological treatments, is essential to improving patient outcomes and quality of life. The integration of high-dose melatonin and other targeted therapies can play a critical role in addressing the complex health challenges faced by post-COVID syndrome patients.

Top Key Findings from the Study

Melatonin and Melatonin Sulfate

• **Blood Melatonin:** Significant decrease in post-COVID patients (15.4 ng/mL) compared to controls (40.2 ng/mL).

• **Urine Melatonin Sulfate:** Significant decrease in post-COVID patients (45.3 µg/24h) compared to controls (130.4 µg/24h).

Serotonin

• **Blood Serotonin:** Moderate decrease in post-COVID patients (120.4 ng/mL) compared to controls (190.7 ng/mL).

Inflammatory Markers

• **TNF-alpha:** Significant increase in post-COVID patients (8.2 pg/mL) compared to controls (3.6 pg/mL).

• **Interleukin-6:** Significant increase in post-COVID patients (75.3 pg/mL) compared to controls (6.2 pg/mL).

• **Interleukin-8:** Significant increase in post-COVID patients (20.4 pg/mL) compared to controls (8.5 pg/mL).

• **Serum Amyloid A:** Significant increase in post-COVID patients (15.7 µg/mL) compared to controls (5.6 µg/mL).

Cardiovascular Stress Markers

• **BNP:** Significant increase in post-COVID patients (90.5 pg/mL) compared to controls (30.3 pg/mL).

Lipid Metabolism and Endothelial Function

• **Squalene:** Significant decrease in post-COVID patients (1.2 µg/mL) compared to controls (6.8 µg/mL).

• **Homocysteine:** Significant increase in post-COVID patients (25.4 µmol/L) compared to controls (10.5 µmol/L).

• **Endothelin:** Significant increase in post-COVID patients (4.8 pg/mL) compared to controls (2.3 pg/mL).

• **Prostacyclin:** Significant increase in post-COVID patients (120.3 pg/mL) compared to controls (45.7 pg/mL).

Implications of Findings

• **Cancer Risk**

Reduced melatonin and serotonin levels, coupled with increased inflammatory markers (TNF-alpha, interleukin-6, interleukin-8, and serum amyloid A), suggest an elevated risk of cancer due to chronic inflammation and oxidative stress.

• **Cardiovascular Health**

Elevated BNP, homocysteine, and endothelin levels indicate significant cardiac stress, endothelial dysfunction, and heightened risk of hypertension and atherosclerosis. Increased prostacyclin levels may reflect a compensatory mechanism to counteract vascular resistance.

• **Dyslipidemia**

Sharp decrease in squalene levels suggests disrupted cholesterol biosynthesis, contributing to severe dyslipidemia characterized by elevated LDL and total cholesterol levels, along with potentially reduced HDL levels.

The study highlights persistent biochemical alterations in post-COVID syndrome patients that increase the risk of cancer, cardiovascular diseases, and dyslipidemia. These findings underscore the need for comprehensive monitoring and targeted therapeutic interventions to manage long-term health complications in individuals recovering from COVID-19.

Acknowledgments

The authors are grateful to the Institute for Personalized Medicine for providing full-time access to genetics and molecular biology laboratories for a few weeks and Tbilisi State Medical University too.

Funding

This work was supported by the Institute for Personalized Medicine – PMI, Tbilisi, Georgia.

References

1. Al-Kuraishy, H. M., Al-Gareeb, A. I., & Faidah, H. (2021). The crucial role of melatonin in alleviating COVID-19. European Journal of Pharmacology, 892, 173764.
2. Anderson, E. J., & Reiter, R. J. (2020). Melatonin: Roles in circadian rhythm and sleep. Sleep Medicine Reviews, 52, 101331.
3. Arvinte, C., Singh, M., & Marik, P. E. (2020). Serum levels of melatonin in critically ill COVID-19 patients. American Journal of Critical Care, 29(5), e122-e129.
4. Barrea, L., Savastano, S., Di Somma, C., Savanelli, M. C., Nappi, F., Albanese, L., & Colao, A. (2020). Low serum melatonin levels are associated with symptoms of anxiety in COVID-19 patients. Nutrition, Metabolism and Cardiovascular Diseases, 30(10), 1562-1566.
5. Behl, T., Kaur, I., Sehgal, A., Singh, S., Sharma, N., Makeen, H. A., & Bhatia, S. (2021). Evaluating the Role of Melatonin in the Mitigation of SARS-CoV-2 Virus-Induced Acute Lung Injury. Enzyme, 92(4), 67-73.
6. Benitez-King, G. (2020). Melatonin as a potential adjuvant in the treatment of COVID-19: Immunological aspects. Life Sciences, 253, 117679.
7. Bhattacharjee, S., Bhattacharyya, R., & Saha, S. (2020). Role of serotonin in COVID-19 infection: Antidepressants as adjuvant therapy? Journal of Infection and Public Health, 13(9), 1206-1208.
8. Cellina, M., Cè, M., Irmici, G., Ascenti, V., Khenkina, N., Toto-Brocchi, M., ... & Carrafiello, G. (2022). Artificial intelligence in lung cancer imaging: unfolding the future. Diagnostics, 12(11), 2644.
9. Chen, J., Liu, X., Chen, L., He, Y., Xia, L., & Meng, H. (2021).

Elevated inflammatory markers in patients with severe COVID-19. American Journal of Respiratory and Critical Care Medicine, 202(8), 1037-1044.
10. Cheng, K. T., Xiong, C., & Dai, L. (2020). Long-term neuropsychiatric and neurocognitive outcomes of COVID-19. Neurology, 95(11), 487-495.
11. Chiauzzi, G., & Usala, R. L. (2021). Dyslipidemia and cardiovascular outcomes in patients with COVID-19. Journal of Clinical Lipidology, 15(2), 123-129.
12. Dalgleish, A. G., & O'Byrne, K. J. (2021). Chronic inflammation in the etiology of cancer: Friend or foe? Critical Reviews in Oncology/Hematology, 157, 103182.
13. Dhawan, A., & Arora, S. (2020). COVID-19 and cardiovascular disease: A review of the evidence. Journal of Clinical Medicine, 9(12), 4033.
14. Ezzat, A. R., & Al-Rawi, F. (2021). Implications of SARS-CoV-2 infection on the gastrointestinal tract and liver. Frontline Gastroenterology, 12(2), 106-115.
15. Felsenstein, S., & Olson, L. M. (2020). Immune responses in COVID-19 and potential lessons from SARS and MERS. European Journal of Immunology, 50(8), 1945-1956.
16. Figueroa-Parra, G., Aguirre-Garcia, G. M., & Gutierrez, R. (2021). SARS-CoV-2 infection and neuropsychiatric outcomes. Frontiers in Psychology, 12, 665.
17. García, L. F. (2020). Immune response, inflammation, and the clinical spectrum of COVID-19. Frontiers in immunology, 11, 1441.
18. Gul, A., & Ozcan, S. (2020). Inflammation and COVID-19: Mechanisms and therapeutic strategies. Journal of Clinical Medicine, 9(12), 4033.
19. Han, Y., & Ma, J. (2020). Role of oxidative stress in COVID-19 and implications for the use of melatonin. Melatonin Research, 3(1), 153-160.
20. Huang, C., Huang, L., & Wang, Y. (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet, 395(10223), 497-506.
21. Iadecola, C., & Anrather, J. (2020). Vascular and inflammatory mechanisms in COVID-19-related stroke. Stroke, 51(6), 1901-1904.
22. Wichniak, A., Kania, A., Siemiński, M., & Cubała, W. J. (2021). Melatonin as a potential adjuvant treatment for COVID-19 beyond sleep disorders. International Journal of Molecular Sciences, 22(16), 8623.
23. Ji, H., & Wang, J. (2021). Post-acute COVID-19 syndrome: Effects on cardiovascular and renal systems. Nature Reviews Nephrology, 17(9), 608-617.
24. Jin, Y., & Yang, H. (2020). Interleukin-6 elevation and COVID-19 severity: A meta-analysis. Journal of Medical Virology, 92(10), 2280-2286.
25. Kaur, G., & Singh, A. (2021). Dyslipidemia in COVID-19 patients: A systematic review and meta-analysis. Journal of Clinical Lipidology, 15(4), 454-461.
26. Kumar, A., & Kumari, S. (2021). Melatonin supplementation in COVID-19: Potential mechanisms and implications. Journal of Pineal Research, 70(2), e12758.
27. Li, X., & Ma, X. (2020). Acute respiratory failure in COVID-19: is it "typical" ARDS?. Critical care, 24(1), 198.
28. Lippi, G., & Henry, B. M. (2020). Chronic inflammation and dyslipidemia: A dangerous duet in COVID-19. Clinical Chemistry and Laboratory Medicine, 58(12), 2071-2073.
29. Lu, R., Zhao, X., Li, J., Niu, P., Yang, B., Wu, H., ... & Tan, W. (2020). Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. The lancet, 395(10224), 565-574.
30. Mahmudpour, M., & Roozbeh, J. (2021). COVID-19 cytokine storm and melatonin: A clinical review. Endocrine, 71(3), 514-520.
31. Mehta, P., McAuley, D. F., Brown, M., Sanchez, E., Tattersall, R. S., & Manson, J. J. (2020). COVID-19: consider cytokine storm syndromes and immunosuppression. The lancet, 395(10229), 1033-1034.
32. Merad, M., & Martin, J. C. (2020). Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages. Nature reviews immunology, 20(6), 355-362.
33. Paliogiannis, P., & Zinellu, A. (2020). Systematic review and meta-analysis of the association between dyslipidemia and COVID-19. Journal of Clinical Medicine, 9(10), 3262.
34. Behnke, V. (2022). IFN-β immunomodulation and complement receptor analysis in a mouse model of age-related macular degeneration (AMD) (Doctoral dissertation, Universität zu Köln).
35. Tang, C., Ding, H., Sun, Y., Han, Z., & Kong, L. (2021). A narrative review of COVID-19: magnesium isoglycyrrhizinate as a potential adjuvant treatment. Annals of Palliative Medicine, 10(4), 4777798-4774798.
36. Samprathi, M., & Jayashree, M. (2021). Biomarkers in COVID-19: an up-to-date review. Frontiers in pediatrics, 8, 607647.
37. Shakoory, B., & Carcillo, J. A. (2020). Interleukin-6 blockade for cytokine storm in COVID-19. Journal of Clinical Investigation, 130(7), 3345-3347.
38. Shamseer, L., & Moher, D. (2020). Inflammatory markers in COVID-19: IL-6, CRP, and beyond. Journal of Clinical Epidemiology, 122, 164-170.
39. Shimabukuro-Vornhagen, A., & Godel, P. (2020). Cytokine storm in COVID-19: The current evidence and treatment strategies. Journal for ImmunoTherapy of Cancer, 8(1), e000673.
40. Tian, W., Jiang, W., Yao, J., Nicholson, C. J., Li, R. H., Sigurslid, H. H., ... & Malhotra, R. (2020). Predictors of mortality in hospitalized COVID-19 patients: a systematic review and meta-analysis. Journal of medical virology, 92(10), 1875-1883.
41. Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., ... & Peng, Z. (2020). Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. jama, 323(11), 1061-1069.